Great Lakes Dredge & Dock (GLDD) – A Nice Win on Boston Harbor

Posted on March 11, 2021 by Admin

Thursday, March 11, 2021

Great Lakes Dredge & Dock (GLDD)
A Nice Win on Boston Harbor

Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. The company only’s operating segments is Dredging. Dredging involves the enhancement or preservation of navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand or rock. Its projects portfolio includes Coastal Restoration, Coastal Protection, Port expansion, and others.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

A Nice Win on Boston Harbor. The Dept of Defense government contract summary indicated that GLDD has been awarded a $61.8 million contract for rock blasting, removal and dredging in Boston Harbor. There were three other bidders and bids were solicited via the internet. Work should start later this year and the estimated completion date is November 2022.

Solid dredging outlook with backlog at $559 million, and potential infrastructure spending creates tailwind. The Boston award is incremental to current low bids pending award/options total ~$562 million, including $90 million added in January …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.

Release – Chakana Copper (CHKKF)(PERU:CA) – Closes Second Tranche of Private Placement Gold Fields Exercises Participation Right

Posted on March 11, 2021 by Admin

Chakana Copper Closes Second Tranche of Private Placement Gold Fields Exercises Participation Right

Vancouver, B.C., March 11,
2021– Chakana Copper Corp. (TSX-V: PERU; OTCQB: CHKKF; FRA: 1ZX) (the “Company” or “Chakana”), is pleased to announce that it has completed a second and final tranche of its non-brokered private placement previously announced on January 20, 2021 (the “Private
Placement”). Pursuant to the second tranche of the Private Placement, the Company sold and issued 3,874,516 common shares of the Company at a price of C$0.50 per common share for gross proceeds of C$1,937,258. In total, Chakana sold and issued an aggregate of 18,060,516 common shares at a price of C$0.50 per common share for gross proceeds of C$9,030,258 pursuant to the Private Placement.

In accordance with an agreement between the Company and Gold Fields Nazca Holdings Inc. (“Gold Fields”), a wholly owned indirect subsidiary of Gold Fields Limited (see news release dated April 19, 2019), Gold Fields exercised its participation right and kept its pro rata ownership interest at 19.99% of the outstanding common shares of Chakana. Gold Fields’ final participation in the Private Placement was the purchase of 6,584,516 common shares for total proceeds of C$3,292,258.

David Kelley, President and CEO commented, “We are pleased to
report that we now have a total of $11 million in working capital to pursue our
aggressive 26,000m drill program and maiden resource estimate as approved
earlier this year. This drill program is undertaking in-fill drilling on
recent discoveries announced at Paloma East, Paloma West, and the Huancarama
Breccia Complex, and will test numerous additional targets. A maiden resource
on several of the breccia pipes will be published this year. We currently have
two drill rigs operating on the Soledad project.”

The Company intends to use the net proceeds of the Private Placement for the accelerated exploration and development of the Company’s high-grade copper-gold-silver Soledad Project located in the Ancash region of Peru and for general working capital and administrative purposes. Since restarting its 15,000m Phase 3 drill program on August 15, 2020, the Company has announced three new discoveries at Paloma East (news release – October 26, 2020), Paloma West (news releases – November 10, November 18, and December 3, 2020), and at the Huancarama Breccia Complex where drilling is ongoing (news release – February 9, January 12, and March 3, 2021).

The Company paid a finder’s fee of C$147,000 on the second tranche of the Private Placement to certain arms-length parties who assisted the Company in introducing subscribers to the Private Placement.

All securities issued for the second tranche under the Private Placement are subject to a four-month hold period expiring on July 11, 2021 in accordance with applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws in jurisdictions outside of Canada. Final closing of this Offering is subject to final acceptance by the TSX Venture Exchange.

About Chakana Copper

Chakana Copper Corp is a Canadian-based minerals exploration company that is currently advancing the high-grade copper-gold-silver Soledad Project located in the Ancash region of Peru, a highly favorable mining jurisdiction with supportive communities. The Soledad Project consists of mineralization hosted in tourmaline breccia pipes. A total of 39,098 metres of drilling has been completed to-date, testing ten (10) of twenty-three (23) confirmed breccia pipes with 110 total targets defined. Chakana’s investors are uniquely positioned as the Soledad Project provides exposure to several metals including copper, gold, and silver. For more information on the Soledad project, please visit the website at www.chakanacopper.com.

ON BEHALF OF THE BOARD
(signed) “David Kelley”
David Kelley
President and CEO

For further information contact:
Joanne Jobin, Investor Relations Officer
Phone: 647 964 0292
Email: jjobin@chakanacopper.com

Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the Exchange) accepts
responsibility for the adequacy or accuracy of this release.

The common shares have not been registered under the United States
Securities Act of 1933, as amended, and may not be offered or sold in the United
States absent registration or an applicable exemption from registration
requirements. This news release does not constitute an offer to sell or a
solicitation of an offer to buy such securities in any jurisdiction in which
such an offer or sale would be unlawful.

Forward-looking Statement Advisory: This release may contain forward-looking statements.
Forward-looking statements involve known and unknown risks, uncertainties, and
other factors which may cause the actual results, performance, or achievements
of Chakana to be materially different from any future results, performance, or
achievements expressed or implied by the forward-looking statements. Forward
looking statements or information relates to, among other things, the
interpretation of the nature of the mineralization at the Soledad copper-gold-silver project (the
“Project”), the potential to expand the mineralization, and
to develop and grow a resource within the Project, the
planning for further exploration work, the ability to de-risk the potential
exploration targets, and our belief in the potential
for mineralization within unexplored parts of the Project. These
forward-looking statements are based on management’s current expectations and
beliefs but given the uncertainties, assumptions and risks, readers are
cautioned not to place undue reliance on such forward- looking statements or
information. The Company disclaims any obligation to update, or to publicly
announce, any such statements, events or developments except as required by
law.

SOURCE: Chakana Copper

Release – Palladium One Mining (NKORF)(PDM:CA) – Drilling at Kaukua South Extends Mineralization Into Gap Zone

Posted on March 11, 2021 by Admin

Palladium One Drilling at Kaukua South Extends Mineralization Into “Gap Zone”

March 11, 2021 –
Toronto, Ontario – Infill drilling spaced at 100-meter grid spacing has increased continuous mineralization to over 1,300 meters and into the ‘gap zone’, thereby supporting the thesis of potentially more open-pit resources at the Kaukua South zone of the Läntinen Koillismaa (“LK”) PGE-Ni-Cu project in Finland said Palladium One Mining Inc. (“Palladium One” or the “Company”) (TSXV: PDM, FRA: 7N11, OTC: NKORF) today. These interim results are from the 17,500-meter, Phase II Resource Definition drill program at Kaukua South.

Derrick Weyrauch, President and CEO of Palladium One said, “Drilling at Kaukua South has successfully extended known mineralization to the east and west of hole LK20-016 and into the ‘gap zone’ where the Induced Polarization (“IP”) chargeability anomaly was weaker (see – hole LK20-036 and LK20-044 in Figure 1). These results imply that the ‘gap zone’ could host more mineralization than previously thought. Interim results demonstrate continuity now over 1,300 meters. As a result of continued success, we have accelerated our plans and commenced a new 50-line kilometer IP survey to extend the Kaukua South strike length, which we believe has the potential to be over seven kilometers in length.”

Highlights

Infill drilling continues to
demonstrate continuity of near surface open pit grades and widths.
Core zones up to 9.0 meters grading 3.1 g/t
Palladium equivalent (“Pd_Eq.”) within 32.7 meters grading 2.0 g/t
Pd_Eq. in hole LK21-034.
First drilling in the “gap zone” returns up to 17.0
meters grading 1.38 g/t Pd_Eq. in hole LK21-044 demonstrating continuity of the mineralization in the Kaukua South IP anomaly.
A new IP survey has been initiated to extend the Kaukua South zone from a drill defined four-kilometer strike length to potentially over seven kilometers.
34 holes totaling 6,404 meters
have been drilled to date on Kaukua South as part of the 17,500-meter Phase II program.

Kaukua South Infill Drilling

Kaukua South infill drilling continues to demonstrate consistent near surface open pit grades and widths. A total of 13 holes from the Phase II drill program on Kaukua South have now been released with intersections of up to 53 meters at 2.1
g/t Pd_Eq*, and a core interval of up to 25 meters at 2.9 g/t Pd_Eq. in hole LK21-028 (see press release January 18, 2021). These 13 holes cover approximately 1.3 kilometers of the Kaukua South Zone, and have returned very similar widths and grades to those in the Kaukua Open Pit resource. (Figure 1 and 2).

Of particular interested is holes LK20-036 and LK20-044 (Figure 2). These represent the first drill holes drilled in the central area of the Kaukua South chargeability anomaly. This central or “gap zone “is approximately a one-kilometer long zone of lower chargeability. The results from these two holes, plus visual results from three additional holes with assays pending, prove that palladium-rich mineralization does extend into this gap zone, which significant increases the potential size of a future Kaukua South resource.

New IP Survey

IP has proven to be highly successful at outlining palladium-rich disseminated copper-nickel sulphide mineralization on the LK Project, the discovery of Kaukua South in an overburden covered area with no previous drilling was a direct result of the Company’s 2020 IP survey.

The success of the Phase II drill program has prompted to the Company to accelerate plans for an additional 50-line kilometre IP survey and a 640-line kilometer drone magnetic survey. The prime objective is to extend the Kaukua South IP chargeability anomaly at least two kilometers to the east onto the Kaukuanjarvi Permit Application area. Regional airborne magnetic data strongly suggests that favourable Kaukua-style mafic-ultramafic hosts rocks extend into this area.

Additionally, the Company believes there is potential to extend Kaukua South at least one kilometer west of the existing 2020 survey grid. The Company plans to re-survey and expand the historic 2008 IP survey which encountered several technical challenges, resulting in amongst other issues, detecting only half of the mineralization associated with the Kaukua Open Pit Resource (Figure 1).

Taken together these two new IP grids could potentially extend the Kaukua South IP chargeability anomaly to over seven kilometers.

Figure 1. Greater Kaukua area plan map, showingcurrent NI 43-101 Kaukua Deposit conceptual pit outline (dashed yellow), Kaukua South and Murtolampi IP chargeability anomalies, and Palladium One drill hole locations. Holes labels in red form part of this release.

Figure 2. Kaukua South Long section looking north

Table 1: Phase II infill drill results to date on Kaukua South

Zone	Hole	From (m)	To (m)	Width (m)	Pd_Eq g/t*	PGE g/t (Pd+Pt+Au)	Pd g/t	Pt g/t	Au g/t	Cu %	Ni %
Kaukua South	LK20-027	103.4	155.0	51.6	1.98	1.07	0.72	0.27	0.08	0.17	0.15
	Inc.	105.6	113.0	7.4	2.58	1.34	0.90	0.31	0.13	0.26	0.18
	And	149.5	155.0	5.5	3.12	1.96	1.34	0.52	0.10	0.27	0.17
	Inc.	153.5	155.0	1.5	6.14	4.09	2.79	1.15	0.15	0.56	0.28
Kaukua South	LK20-028	42.6	95.5	52.9	2.06	1.44	1.00	0.36	0.08	0.11	0.11
	Inc.	46.9	72.0	25.1	2.92	2.08	1.44	0.52	0.12	0.17	0.14
	Inc.	50.5	60.0	9.5	3.56	2.52	1.75	0.61	0.16	0.23	0.16
Kaukua South	LK20-029	37.5	62.9	25.4	2.57	1.87	1.30	0.46	0.11	0.15	0.11
	Inc.	47.0	62.0	15.0	3.16	2.36	1.65	0.58	0.13	0.17	0.13
	Inc.	56.5	62.0	5.5	4.34	3.36	2.36	0.82	0.18	0.20	0.16
	Inc	56.5	57.7	1.2	6.15	4.97	3.54	1.26	0.17	0.25	0.21
Kaukua South	LK20-030	26.4	86.5	60.1	1.88	1.00	0.68	0.24	0.07	0.17	0.14
	Inc.	47.0	68.0	21.0	2.44	1.43	0.98	0.35	0.10	0.21	0.16
	Inc.	53.0	54.5	1.5	3.94	2.69	1.78	0.78	0.12	0.28	0.20
Kaukua South	LK20-031	17.9	61.5	43.6	1.94	1.12	0.76	0.27	0.09	0.16	0.13
	Inc.	17.9	55.5	37.6	2.17	1.25	0.85	0.30	0.10	0.19	0.14
	Inc.	24.5	35.0	10.5	2.81	1.60	1.09	0.39	0.11	0.27	0.18
Kaukua South	LK20-032	60.3	108.3	48.0	1.81	0.84	0.57	0.21	0.06	0.16	0.16
	Inc.	61.4	75.0	13.7	2.12	0.90	0.58	0.23	0.09	0.22	0.20
Kaukua South	LK20-033	41.3	85.0	43.7	1.76	0.87	0.58	0.21	0.07	0.18	0.14
	Inc.	42.7	56.3	13.7	2.33	1.21	0.83	0.28	0.10	0.21	0.18
Kaukua South	LK20-034	86.9	119.5	32.7	2.05	1.16	0.81	0.26	0.09	0.16	0.15
	Inc.	88.5	112.5	24.0	2.26	1.32	0.93	0.29	0.10	0.17	0.15
	Inc.	88.5	97.5	9.0	3.06	1.98	1.41	0.45	0.12	0.20	0.17
	Inc.	94.5	96.0	1.5	4.20	2.94	2.15	0.66	0.14	0.25	0.20
Kaukua South	LK20-035	66.0	118.0	52.0	1.32	0.63	0.44	0.15	0.04	0.11	0.11
	Inc	67.5	69.0	1.5	3.49	2.44	2.10	0.27	0.07	0.23	0.15
	And	95.5	104.7	9.2	2.04	1.23	0.80	0.32	0.11	0.17	0.13
Kaukua South	LK20-036	245.3	280.0	34.6	1.05	0.39	0.25	0.11	0.03	0.10	0.11
	Inc.	257.5	280.0	22.5	1.17	0.47	0.31	0.12	0.04	0.13	0.11
	Inc.	259.0	260.5	1.5	1.72	0.86	0.62	0.16	0.07	0.15	0.14
Kaukua South	LK20-042	115.5	158.9	43.4	1.41	0.77	0.53	0.19	0.05	0.09	0.12
	Inc.	118.5	123.0	4.5	2.29	1.23	0.82	0.32	0.09	0.14	0.19
	And	133.0	146.5	13.5	1.71	1.04	0.74	0.25	0.06	0.09	0.12
	Inc.	143.5	146.5	3.0	1.97	1.47	1.13	0.28	0.06	0.08	0.09
Kaukua South	LK20-043	131.5	162.3	30.8	1.24	0.55	0.36	0.15	0.04	0.11	0.12
	Inc.	133.0	136.0	3.0	2.05	1.16	0.82	0.32	0.02	0.05	0.20
	And	187.4	188.5	1.1	2.00	1.54	1.09	0.40	0.05	0.07	0.09
Kaukua South	LK20-044	156.8	173.8	17.0	1.38	0.62	0.41	0.14	0.06	0.14	0.12
	Inc.	156.8	169.5	12.7	1.58	0.71	0.48	0.17	0.07	0.16	0.14
	Inc.	166.0	169.5	3.4	2.10	1.07	0.73	0.25	0.08	0.20	0.16

* Reported widths are “drilled widths” not true widths.
** Orange shaded values previously released (see press release January 18, 2021)

*Palladium Equivalent
Palladium equivalent is calculated using US$1,100 per ounce for palladium, US$950 per ounce for platinum, US$1,300 per ounce for gold, US$6,614 per tonne for copper, and US$15,4332 per tonne for nickel. This calculation is consistent with the calculation in the Company’s September 2019 NI 43-101 Kaukua resource estimate.

QA/QC
The Phase I drilling program was carried out under the supervision of Neil Pettigrew, M.Sc., P. Geo., Vice President of Exploration and a director of the Company.

Drill core samples were split using a rock saw by Company staff, with half retained in the core box and stored indoors in a secure facility, in Taivalkoski, Finland. The drill core samples were transported by courier from the Company’s core handling facility in Taivalkoski, Finland, to ALS Global (“ALS”) laboratory in Outokumpu, Finland. ALS, is an accredited lab and are ISO compliant (ISO 9001:2008, ISO/IEC 17025:2005). PGE analysis was performed using a 30 grams fire assay with an ICP-MS or ICP-AES finish. Multi-element analyses, including copper and nickel were analysed by four acid digestion using 0.25 grams with an ICP-AES finish.

Certified standards, blanks and crushed duplicates are placed in the sample stream at a rate of one QA/QC sample per 10 core samples. Results are analyzed for acceptance at the time of import. All standards associated with the results in this press release were determined to be acceptable within the defined limits of the standard used.

Qualified Person
The technical information in this release has been reviewed and verified by Neil Pettigrew, M.Sc., P. Geo., Vice President of Exploration and a director of the Company and the Qualified Person as defined by National Instrument 43-101.

About Palladium One
Palladium One Mining Inc. is an exploration company targeting district scale, platinum-group-element (PGE)-copper nickel deposits in Finland and Canada. Its flagship project is the Läntinen Koillismaa or LK Project, a palladium dominant platinum group element-copper-nickel project in north-central Finland, ranked by the Fraser Institute as one of the world’s top countries for mineral exploration and development. Exploration at LK is focused on targeting disseminated sulfides along 38 kilometers of favorable basal contact and building on an established NI 43-101 open pit resource.

ON BEHALF OF THE BOARD
“Derrick
Weyrauch”
President & CEO,
Director

For further information contact: Derrick Weyrauch, President
& CEO
Email: info@palladiumoneinc.com

Neither the TSX Venture Exchange nor its Market Regulator (as
that term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.

This
press release includes “forward-looking information” that is subject
to a few assumptions, risks and uncertainties, many of which are beyond the
control of the Company. Statements regarding listing of the Company’s common
shares on the TSXV are subject to all of the risks and uncertainties normally
incident to such events. Investors are cautioned that any such statements are
not guarantees of future events and that actual events or developments may
differ materially from those projected in the forward-looking statements. Such
forward-looking statements represent management’s best judgment based on
information currently available. Factors that could cause the actual results to
differ materially from those in forward-looking statements include regulatory actions
and general business conditions. Such forward-looking information reflects the
Company’s views with respect to future events and is subject to risks,
uncertainties and assumptions, including those set out in the Company’s annual
information form dated April 29, 2020 and filed under the Company’s profile on
SEDAR at www.sedar.com.
The Company does not undertake to update forward?looking
statements or forward?looking information,
except as required by law. Investors are cautioned that any such statements are
not guarantees of future performance and actual results or developments may
differ materially from those projected in the forward-looking statements.

Source: Palladium One Mining Inc.

Release – Helius Medical Technologies (HSDT) – Reports Fourth Quarter and Full Year 2020 Financial Results

Posted on March 11, 2021 by Admin

Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results

NEWTOWN, Pa., March 10, 2021 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported financial results for the quarter and full year ended December 31, 2020.

Fourth Quarter and Recent Business Updates

The Company closed a private placement for total net proceeds of approximately $3.2 million and an underwritten public offering of units for net proceeds of approximately $9.6 million.
• Helius expects its existing capital, including net proceeds from the public offering that closed and net proceeds raised through the exercise of warrants in the first quarter of 2021, will be sufficient to fund the Company’s operations into the first quarter of 2022.
The Company announced on January 11, 2021 that it submitted its formal response to the U.S. Food and Drug Administration’s (the “FDA”) request for additional information, related to Helius’ request for de novo classification and clearance of the PoNS device.
The Company received written notice from The Nasdaq Stock Market LLC on January 19, 2021 that Helius is in compliance with all applicable listing standards.
The Centers for Medicare & Medicaid Services (“CMS”) announced that it is finalizing a new coverage pathway, Medicare Coverage of Innovative Technology, or “MCIT,” for FDA-designated breakthrough medical devices cleared by FDA.
• The MCIT rule will provide national Medicare coverage as early as the same day as FDA market authorization for breakthrough devices and coverage would last for four years.

Fourth Quarter 2020 Financial Summary

Revenue of $191 thousand, compared to revenue of $152 thousand in fourth quarter of 2019.
Operating loss of $3.0 million, compared to operating loss of $5.6 million in fourth quarter of 2019.
Net loss of $2.5 million, compared to net loss of $5.3 million in fourth quarter of 2019.

Full Year 2020 Financial Summary

Revenue of $0.7 million, compared to revenue of $1.5 million in 2019.
Operating loss of $14.4 million, compared operating loss of $24.0 million in 2019.
Net loss of $14.1 million, compared to net loss of $9.8 million in 2019.
As of December 31, 2020, the Company had cash of $3.3 million, compared to $5.5 million at December 31, 2019. The Company had no debt outstanding at December 31, 2020.

“During the fourth quarter, we were pleased with our pace of progress and the commitment our employees have shown in view of the continued headwinds created by the COVID-19 pandemic,” said Dane Andreeff, Interim President and Chief Executive Officer of Helius. “Our regulatory team focused on preparing a thorough response to FDA’s request for additional information related to our request for U.S. de novo classification and clearance in MS. As a result of their efforts, we were pleased to announce the submission of our response on January 11th, and we hope to receive de novo classification and clearance during the first half of 2021. In Canada, while we continued to see the impacts of COVID on the clinics we serve and their patients, our commercial team successfully expanded our network of authorized PoNS clinics from 7 to 31 locations by year-end, exceeding our goal. Subsequent to quarter-end, we also secured approximately $11 million to strengthen our balance sheet and support our operations going forward.”

“As we enter 2021, Helius is focused on securing regulatory clearance and coverage for our breakthrough PoNS device in the U.S. while supporting our recently expanded network of Canadian clinics. With our U.S. de novo submission in MS under review, a network of 31 clinics in Canada and an enhanced balance sheet, we believe we are well-positioned to weather the continued effects of the pandemic and expand the availability of our PoNS Treatment going forward. We remain committed to executing on our regulatory and commercial strategies as effectively and efficiently with the ultimate goal of bringing our innovative PoNS Treatment to the aid of as many patients as possible.”

Fourth Quarter 2020 Financial Results

Total revenue for the fourth quarter of 2020 was $191 thousand, compared to $152 thousand in the fourth quarter of 2019. Product sales represented approximately 96% of total revenue in the fourth quarter of 2020 compared to 100% of total revenue in the fourth quarter of 2019. Product sales in both periods were generated through sales of the PoNS device pursuant to supply agreements with PoNS Authorized clinic locations in Canada. License and fee revenue represented 4% of sales in the fourth quarter of 2020, compared to 0% of sales in the fourth quarter of 2019.

Gross loss for the fourth quarter of 2020 was $10 thousand, compared to gross loss of $156 thousand in the fourth quarter of 2019. Operating expenses for the fourth quarter of 2020 decreased $2.5 million, or 45% year-over-year, to $3 million, compared to $5.5 million in the fourth quarter of 2019.

Operating loss for the fourth quarter of 2020 decreased $2.6 million, or 47% year-over-year, to $3.0 million, compared to $5.6 million in the fourth quarter of 2019.

Total other income for the fourth quarter of 2020 was $468 thousand, compared to $294 thousand in the fourth quarter of 2019.

Net loss for the fourth quarter of 2020 was $2.5 million, or $(1.77) per basic and diluted common share, compared to a net loss of $5.3 million, or $(6.71) per basic and diluted common share, in the fourth quarter of 2019. Weighted average shares used to compute basic and diluted net loss per common share were 1.4 million and 0.8 million for the fourth quarter of 2020 and 2019, respectively.

Full Year 2020 Financial Results

Total revenue for the full year 2020 was $0.7 million, compared to $1.5 million for full year 2019. Product sales represented 95% of total revenue for full year 2020, compared to 97% of total for full year 2019. Product sales in both periods were generated through sales of the PoNS device pursuant to supply agreements with PoNS Authorized clinic locations in Canada. License and fee revenue represented 5% of total revenue for full year 2020, compared to 3% of total revenue for the full year 2019.

Gross profit for full year 2020 was $0.3 million, compared to gross profit of $0.7 million for full year 2019. Operating expenses for full year 2020 decreased $9.9 million, or 41% year-over-year, to $14.7 million, compared to $24.6 million for full year 2019.

Operating loss full year 2020 decreased $9.6 million, or 40% year-over-year, to $14.4 million, compared to operating loss of $24.0 million for full year 2019.

Total other income for full year 2020 was $0.3 million, compared to $14.2 million of other income for full year 2019. The year-over-year change is driven primarily by the change in fair value of derivative instruments which is primarily attributable to the change in our stock price, volatility and the number of derivative financial instruments being measured during the period.

Net loss for full year 2020 was $14.1 million, or $(11.80) per basic and diluted common share, compared to net loss of $9.8 million, or $(12.99) per basic and diluted common share, for full year 2019. Weighted average shares used to compute basic and diluted net loss per share were 1.2 million and 0.8 million for full year 2020 and full year 2019, respectively.

Net cash provided by financing activities during the twelve months ended December 31, 2020 was $9.6 million.

As of December 31, 2020, the Company had cash of $3.3 million, compared to $5.5 million at December 31, 2019. The Company had no debt outstanding at December 31, 2020.

Full Year 2021 Outlook

The Company is not providing a formal financial outlook for the full year 2021 at this time, given the continued uncertainty on the duration and impact of the COVID-19 pandemic on its financial and operating results.

Conference Call

Management will host a conference call at 5:00 p.m. Eastern Time on March 10, 2021 to discuss the results of the quarter and business outlook. Those who would like to participate may dial 877-407-2988 (201-389-0923 for international callers) and provide access code 13715793. A live webcast of the call will also be provided on the Events section of the Company’s investor relations website at:

https://heliusmedical.com/index.php/investor-relations/events/upcoming-events.

For those unable to participate, a replay of the call will be available for two weeks at 877-660-6853 (201-612-7415 for international callers); access code 13715793. The webcast will be archived on the Events section of the Company’s investor relations website.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS™). For more information, visit www.heliusmedical.com.

About the PoNS Device and PoNS Treatment

The Portable Neuromodulation Stimulator (PoNS™) is an authorized class II, non-implantable, medical device in Canada intended for use as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from multiple sclerosis (MS), and chronic balance deficit due to mild-to-moderate traumatic brain injury (mmTBI) and is to be used in conjunction with physical therapy. The PoNS™ is an investigational medical device in the United States, the European Union (“EU”), and Australia (“AUS”). The device is currently under review for de novo classification and clearance by the FDA. It is also under premarket review by the AUS Therapeutic Goods Administration. PoNS™ is currently not commercially available in the United States, the European Union or Australia.

Cautionary Disclaimer Statement:

Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as “believe,” “continue,” “expect,” “look forward,” “will” and similar expressions. Such forward-looking statements include, among others, statements regarding the COVID-19 pandemic, including its impact on the Company, the Company’s future growth and operational progress, including clinical and regulatory development plans for the PoNS device, the Company’s expectations regarding the sufficiency of funds for anticipated future operations, potential receipt of regulatory clearance of the PoNS device in the United States, the success of the Company’s planned study, business and commercialization initiatives and objectives, and expectations for full year 2021.

There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include uncertainties associated with the clinical development process and FDA regulatory submission and approval process, including that the Company’s request for de novo classification and clearance may be declined by the FDA, that the FDA is not required to and may not respond to the Company’s request in the timeframe indicated by its de novo review goals or in the time the Company expects, whether the Company’s response will be satisfactory to the FDA, whether the FDA will require additional information, whether the Company will be able to provide it in a timely manner and whether such additional information will be satisfactory to the FDA, the impact of the COVID-19 pandemic, uncertainties associated with clinical trial enrollments and the results of the planned study, uncertainties associated with the clinical development process and FDA regulatory submission and approval process, including the Company’s capital requirements to achieve its business objectives and other risks detailed from time to time in the filings made by the Company with securities regulators, and including the risks and uncertainties about the Company’s business described in the “Risk Factors” sections of the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at www.sec.gov or www.sedar.com.

The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.

The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Helius Medical Technologies, Inc.
Unaudited Consolidated Balance Sheets
(Except for share data, amounts in thousands)

	December 31, 2020			December 31, 2019
ASSETS
Current assets
Cash	$	3,331		$	5,459
Accounts receivable, net		74			210
Other receivables		156			364
Inventory, net		389			598
Prepaid expenses		735			610
Total current assets		4,685			7,241
Property and equipment, net		486			712
Other assets
Goodwill		759			1,242
Intangible assets, net		527			582
Operating lease right-of-use asset, net		90			552
Other assets		—			18
Total other assets		1,376			2,394
TOTAL ASSETS	$	6,547		$	10,347
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable	$	747		$	1,676
Accrued liabilities		1,337			1,519
Operating lease liability		59			172
Derivative financial instruments		—			5
Deferred revenue		281			430
Total current liabilities		2,424			3,802
Non-current liabilities
Operating lease liability		32			465
Deferred revenue		220			245
TOTAL LIABILITIES		2,676			4,512
STOCKHOLDERS’ EQUITY
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2020 and December 31, 2019		—			—
Class A Common stock, $0.001 par value; 150,000,000 shares authorized; 1,484,362 and 877,672 shares issued and outstanding as of December 31, 2020 and December 31, 2019, respectively		1			1
Additional paid-in capital		123,872			111,509
Accumulated other comprehensive loss		(1,099	)		(902	)
Accumulated deficit		(118,903	)		(104,773	)
TOTAL STOCKHOLDERS’ EQUITY		3,871			5,835
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	6,547		$	10,347

Helius Medical Technologies, Inc.
Unaudited Consolidated Statements of Operations and Comprehensive Loss
(Amounts in thousands except share and per share data)

	Three Months Ended						Year Ended
	December 31,						December 31,
	2020			2019			2020			2019
Revenue:
Product sales, net	$	184		$	159		$	625		$	1,454
Fee revenue		—			(12	)		9			37
License revenue		7			5			27			5
Total operating revenue		191			152			661			1,496
Cost of sales:
Cost of product sales		201			308			388			846
Gross profit		(10	)		(156	)		273			650
Operating expenses:
Research and development		827			1,599			4,582			8,061
Selling, general and administrative		2,089			3,806			9,714			16,521
Amortization expense		76			64			363			64
Total operating expenses		2,992			5,469			14,659			24,646
Operating loss		(3,002	)		(5,625	)		(14,386	)		(23,996	)
Other income:
Other income		—			60			63			95
Change in fair value of derivative financial instruments		—			80			4			14,113
Foreign exchange gain		468			154			189			7
Total other income		468			294			256			14,215
Net loss		(2,534	)		(5,331	)		(14,130	)		(9,781	)
Other comprehensive loss:
Foreign currency translation adjustments		(406	)		(143	)		(197	)		(311	)
Comprehensive loss	$	(2,940	)	$	(5,474	)	$	(14,327	)	$	(10,092	)
Net loss per share
Basic	$	(1.77	)	$	(6.71	)	$	(11.80	)	$	(12.99	)
Diluted	$	(1.77	)	$	(6.71	)	$	(11.80	)	$	(12.99	)
Weighted average shares outstanding
Basic		1,430,504			793,934			1,197,774			752,932
Diluted		1,430,504			793,934			1,197,774			752,932

Helius Medical Technologies, Inc.
Unaudited Condensed Consolidated Statements of Cash Flows
(Amounts in thousands)

	Year Ended
	December 31,
	2020			2019
Cash flows from operating activities:
Net loss	$	(14,130	)	$	(9,781	)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of derivative financial instruments		(4	)		(14,113	)
Stock-based compensation expense		2,529			4,691
Unrealized foreign exchange (gain) loss		(182	)		70
Depreciation expense		119			127
Amortization expense		363			64
Provision for doubtful accounts		140			220
Provision for inventory reserve		205			50
Intangible asset impairment		184			—
Loss from disposal of property and equipment		110			—
Gain from lease modification		(56	)		—
Changes in operating assets and liabilities:
Accounts receivable		(4	)		(438	)
Other receivables		226			(278	)
Inventory		4			(256	)
Prepaid expenses		(125	)		(163	)
Other current assets		—			264
Operating lease liability		(28	)		(13	)
Accounts payable		(635	)		(1,116	)
Accrued liabilities		(280	)		(327	)
Deferred revenue		(174	)		—
Net cash used in operating activities		(11,738	)		(20,999	)
Cash flows from investing activities:
Purchase of property and equipment		(63	)		(278	)
Proceeds from sale of property and equipment		61			—
Business acquisitions, net of cash acquired		—			(416	)
Internally developed software		(7	)		(75	)
Net cash used in investing activities		(9	)		(769	)
Cash flows from financing activities:
Proceeds from the issuance of common stock and accompanying warrants		10,653			1,685
Share issuance costs		(1,015	)		(247	)
Proceeds from the exercise of stock options and warrants		—			215
Proceeds from Paycheck Protection Program Loan		323			—
Repayment of Paycheck Protection Program Loan		(323	)		—
Net cash provided by financing activities		9,638			1,653
Effect of foreign exchange rate changes on cash		(19	)		(9	)
Net decrease in cash		(2,128	)		(20,124	)
Cash at beginning of year		5,459			25,583
Cash at end of year	$	3,331		$	5,459

Investor Relations Contact:

Westwicke Partners on behalf of Helius Medical Technologies, Inc.
Jack Powell, Vice President
investorrelations@heliusmedical.com

SOURCE: Helius Medical Technologies, Inc.

Release – PDS Biotechnology (PDSB) – COVID-19 Vaccine Consortium Received a Commitment from Brazil (MCTI)

Posted on March 11, 2021 by Admin

PDS Biotech Announces that its COVID-19 Vaccine Consortium Received a Commitment from The Ministry of Science, Technology and Innovation of Brazil (MCTI) to fund Clinical Development and Commercialization of PDS0203 with an Award of up to ~US$60 Million

Development and
commercialization of novel T-cell activating vaccine to be performed in Brazil
by consortium of PDS Biotech, Farmacore Biotechnology and Blanver Farmoquímica

FLORHAM PARK, N.J., March 11, 2021 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on PDS Biotech’s proprietary Versamune^® T-cell activating technology, today announced that its COVID-19 vaccine consortium consisting of PDS Biotech, Farmacore Biotechnology and Blanver Farmoquímica, has received a commitment from the Secretary for Research and Scientific Training of the MCTI to fund up to approximately US$60 million to support the clinical development and commercialization of a novel, Versamune^®-based, second generation COVID-19 vaccine in Brazil.

MCTI intends to start making the funds available to prepare to perform a combined Phase 1/2 clinical trial, upon authorization by the Brazilian regulatory agency, Agência Nacional de Vigilância Sanitária (Anvisa) to initiate the proposed Versamune^®-based COVID-19 vaccine clinical program in Brazil.

The pre-IMPD package for the Phase 1/2 trial is currently under review by Anvisa and the trial is anticipated to begin by Q2/3 2021. The majority of the capital provided by MCTI will fund the manufacturing process scale up, production and the Phase 3 trial, pending the results of the Phase 1/2 trial. The consortium members will work under a mutually agreed work plan to guide the vaccine efficiently through development in compliance with regulatory standards. The consortium anticipates working to initiate manufacturing scale up activities in the second quarter.

This award is based on the preclinical studies of the Versamune^®-based COVID-19 vaccine. The vaccine combines PDS Biotech’s Versamune^® T-cell activating platform technology with a SARS-CoV-2 recombinant protein derived from the spike (S) protein. Notably, the protein in this fully synthetic vaccine includes conserved and non-mutating regions of the virus. The vaccine has demonstrated strong potential in preclinical studies to efficiently promote the induction of killer (CD8+) and helper (CD4+) T-cells that recognize and induce immune responses against such non-mutating regions of the virus. The protein also includes regions of the spike protein that result in the induction of neutralizing antibodies.

The Phase 1 and 2 trials, which will be run together, are anticipated to enroll approximately 360 patients and will assess the safety and efficacy of the vaccine as well as both the antibody and killer T-cell responses induced by the vaccine to the novel coronavirus. The clinical trials are planned to be conducted in Brazil.

“PDS Biotech and Farmacore Biotechnology have taken the important step of advancing our Versamune^®-based COVID-19 vaccine into the clinic,” said Dr. Frank Bedu-Addo, Chief Executive Officer of PDS Biotech.“ The preclinical results demonstrate the vaccine’s potential to induce a broad range of robust anti SARS-CoV-2 immune responses. The rapidly increasing number of SARS-CoV-2 mutations highlights the need for novel, second generation vaccines capable of generating both killer and helper T-cells that can recognize and attack conserved and non-mutating regions of the virus. We applaud Farmacore Biotechnology and Blanver Farmoquímica for reaching this important milestone and look forward to the results of the planned human clinical trials and hopefully a rapid advancement towards commercialization of the product. These clinical trials will also advance our understanding of the potential for novel Versamune^®-based vaccines to provide long-term protection against infection with viruses with pandemic potential such as SARS-CoV-2.”

“We are excited to continue advancing the program with PDS Biotech, and we are thrilled to have had the continued support of the Brazilian government as we finalize clinical study protocols with Anvisa for human testing of the novel vaccine combining the Versamune^® T-cell activating technology with the SARS-CoV-2 recombinant protein antigen. We are proud to advance this promising medicine in Brazil in the fight against this global pandemic,” said Helena Faccioli, CEO of Farmacore Biotechnology.

As the license holder of PDS0203 in Latin America, Farmacore Biotechnology will continue to lead the regulatory and clinical trial efforts in Brazil and has selected a top clinical research organization, to conduct clinical trials in Brazil. PDS Biotech will continue to contribute scientific expertise and operational support and oversee scale up of the manufacturing process. Blanver Farmoquímica will manufacture, promote, distribute, and commercialize the Versamune^®-based COVID-19 vaccine in Latin America.

All funding is contingent on the availability of financial resources within the MCTI, and The Secretary for Research and Scientific Training of the MCTI has committed to making every effort to finance all clinical and development stages of the program.

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune^® T-cell activating technology platform. Versamune^® effectively delivers disease-specific antigens for
in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune^® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

About Farmacore Biotechnology

Farmacore Biotechnology is a biotechnology company, founded in 2005, focusing on R&D of innovative immunobiological products for use in the human and veterinary health sectors. It is a technology-based company that conducts research and development of biotechnological products and processes for the human and veterinary sectors. It develops innovative biotechnological and immunobiological products and adds value to them in all stages of development, from project design to biomolecule production www.farmacore.com.br.

About Blanver Farmoquímica

Blanver Farmoquímica e Farmacêutica S.A. is a Brazilian company, founded in 1984, focused on R&D, manufacture and sale of innovative medicines and active pharmaceutical ingredients. The company plays in the segments of HIV, Hepatitis, Oncology and Hematology, providing high quality products for expanding the population’s access to medicines through partnerships with the Ministry of Health and official laboratories. Blanver Farmoquímica is committed in always looking for innovations that will improve people’s health and quality of life.

About PDS0203

PDS0203 is an investigational vaccine designed for the prevention of COVID-19 being jointly developed for Latin America by a consortium that includes PDS Biotech, Farmacore Biotechnology and Blanver Farmoquímica. The vaccine combines the utility of PDS Biotech’s Versamune^® platform with a recombinant native Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) protein recognizable by our immune system (antigen). The Versamune^® platform, due to its unique ability to induce both antibody and polyfunctional CD8+ killer and CD4+ helper T-cell responses is being utilized to develop a next generation vaccine that may more effectively prevent COVID-19.

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast.” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS0101 and PDS0203 ; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0101 and PDS0203 and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the acceptance by the market of the Company’s product candidates, if approved; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Company’s product candidates; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to the COVID-19 pandemic. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company’s annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Media & Investor Relations Contact:

Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
Email: drandolph@pdsbiotech.com

Jacob Goldberger
CG Capital
Phone: +1 (404) 736-3841
Email: jacob@cg.capital

SOURCE: PDS Biotechnology

PDS Biotechnology Corp (PDSB) – Versamune-based COVID-19 Vaccine Consortium Received Brazilian Government Grant

Posted on March 11, 2021 by Admin

Thursday, March 11, 2021

PDS Biotechnology Corp (PDSB)
Versamune-based COVID-19 Vaccine Consortium Received Brazilian Government Grant

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is primarily engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

Ahu Demir, Ph. D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Supporting funding of $US60 million for the coronavirus program. PDS Biotech, Farmacore, and Blanver consortium received a commitment from the Secretary for Research and Scientific Training of the Ministry of Science, Technology, and Innovation of Brazil (MCTI). The funding of approximately US$60 million will be used to support the clinical development and commercialization of a novel, Versamune-based, second-generation COVID-19 vaccine in Brazil.

Near-term value-generating catalysts. We believe the company has multiple inflection points to generate value including a) PDS0101 preliminary efficacy data anticipated in Q2 2021 and b) PDS0203 safety and immunogenicity data projected in Q4 2021/Q1 2022 …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Release – Capstone Turbine (CPST) – Enters Into A New OEM Agreement With European-Based B K

Posted on March 11, 2021 by Admin

Capstone Turbine Enters Into A New Original Equipment Manufacturer (OEM) Agreement With European-Based Clean Energy Company, B+K – Expanding The Application Of Microturbine Technologies Not Reliant On Fossil Fuels

Capstone Immediately Receives Order for First Commercial Unit

VAN NUYS, CA / ACCESSWIRE / March 11, 2021 / Capstone Turbine Corporation (www.capstoneturbine.com) (NASDAQ:CPST), the world’s leading manufacturer of clean energy technology microturbine systems, announced today that it continues to expand the range of non-fossil fuels able to power its innovative microturbine based energy solutions. With the signing of a new OEM agreement with Professor Dr. Berg & Kießling GmbH (B+K) (www.bergundkiessling.com), Capstone immediately received an order for the first Capstone microturbine kit under the new agreement.

The Capstone microturbines will be integrated into the innovative B+K ClinX product. The ClinX product uses renewable sources instead of fossil fuels and thus prevents unnecessary CO2 emissions. ClinX enables the decentralized conversion of previously unused wooden byproducts into heat and electricity. A unique feature of ClinX is its relatively small size of <1 MW, which works well for decentralized energy applications, and it has a broad fuel spectrum. ClinX burns heterogeneous, wooden byproducts and thus converts heat and at the same time produces electricity using the externally fired Capstone microturbine.

“B+K was founded back in 2012 to develop decentralized combined heat and power (CHP) systems based on microturbine technology, and we are proud that after many years of collaboration, B+K has officially selected Capstone technology for their innovative ClinX product,” said Darren Jamison, Capstone’s President and Chief Executive Officer. “Capstone is committed to finding better ways to generate green energy for distributed generation and CHP applications using renewable natural gas, biogas, hydrogen or externally fired thermal solutions like the B+K ClinX,” Mr. Jamison added.

The ClinX solution provides a more environmentally-friendly solution as customers convert energy from renewable energy sources instead of fossil fuels. This renewable energy generation helps to avoid additional CO2 emissions and to protect the environment. The use of professional filter systems guarantees compliance with stringent air quality standards. Depending on the input, the remaining ashes may also subsequently be used in agriculture and forestry.

“In addition to supplying microturbine kits to B+K, Capstone’s factory project team will support the sale of the ClinX solution with its new Direct Sales organization and with our existing global Distribution network,” said Jim Crouse, Capstone’s Chief Revenue Officer. “The B+K containerized design will allow for quick deployment and easy installation,” Mr. Crouse added.

ClinX is a modular system that is adapted to customers’ requirements. The ClinX 50 will utilize Capstone’s proven C65 microturbine, and the ClinX 150 will incorporate Capstone’s highly reliable C200 microturbine. The systems will be expandable in a user-friendly manner as the central combustion unit with a subsequent energy conversion module will be able to be supplemented by a cooling or water treatment module if required.

“Capstone is a company that excels globally in clean and environmentally-friendly turbine solutions,” said Sebastian Kiessling, Executive Partner of B+K. “Capstone lives our mission statement together with us, and we are looking forward to long-term cooperation and many successful joint projects,” concluded Mr. Kiessling.

About Capstone Turbine Corporation

Capstone Turbine Corporation (www.capstoneturbine.com) (NASDAQ:CPST) is the world’s leading producer of highly efficient, low-emission, resilient microturbine energy systems. Capstone microturbines serve multiple vertical markets worldwide, including natural resources, energy efficiency, renewable energy, critical power supply, transportation and microgrids. Capstone offers a comprehensive product lineup via our direct sales team, as well as our global distribution network. Capstone provides scalable solutions from 30 kWs to 10 MWs that operate on a variety of fuels and are the ideal solution for today’s multi-technology distributed power generation projects.

For customers with limited capital or short-term needs, Capstone offers rental systems; for more information, contact: rentals@capstoneturbine.com. To date, Capstone has shipped nearly 10,000 units to 83 countries and in FY20, saved customers an estimated $219 million in annual energy costs and 368,000 tons of carbon.

For more information about the company, please visit www.capstoneturbine.com. Follow Capstone Turbine on Twitter, LinkedIn, Instagram, Facebook and YouTube.

Cautionary Note Regarding Forward-Looking Statements

This release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including statements regarding expectations, beliefs, plans, intentions and strategies of the Company. The Company has tried to identify these forward-looking statements by using words such as “expect,” “anticipate,” “believe,” “could,” “should,” “estimate,” “intend,” “may,” “will,” “plan,” “goal” and similar terms and phrases, but such words, terms and phrases are not the exclusive means of identifying such statements. Actual results, performance and achievements could differ materially from those expressed in, or implied by, these forward-looking statements due to a variety of risks, uncertainties and other factors, including, but not limited to, the following: the ongoing effects of the COVID-19 pandemic; the availability of credit and compliance with the agreements governing the Company’s indebtedness; the Company’s ability to develop new products and enhance existing products; intense competition; financial performance of the oil and natural gas industry and other general business, industry and economic conditions; the Company’s ability to adequately protect its intellectual property rights; and the impact of pending or threatened litigation. For a detailed discussion of factors that could affect the Company’s future operating results, please see the Company’s filings with the Securities and Exchange Commission, including the disclosures under “Risk Factors” in those filings. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. “Capstone” and “Capstone Microturbine” are registered trademarks of Capstone Turbine Corporation. All other trademarks mentioned are the property of their respective owners.

CONTACT:
Capstone Turbine Corporation
Investor and investment media inquiries:
818-407-3628

ir@capstoneturbine.com

SOURCE: Capstone Turbine Corporation

How Much is a Trillion?

Posted on March 11, 2021 by Admin

$1.9 Trillion in Terms we can Better Relate To

Whether one finds the new $1.9 Trillion Covid Relief Bill heartwarming or blood-boiling is a matter of personal philosophy. What we can all agree on related to the stimulus package, The American Rescue Plan, is that it is a lot of money – a trillion is a very big number that most of us can not even fathom.

Two Ways to
Better Comprehend a Trillion

Rather than just use the word “huge” to describe a trillion, or even $1.9 trillion, I want to put it in terms that are better understood. Using my trusted HP 12c, I began entering the number one trillion and quickly found that my 20-year-old calculator only allowed for nine zeros — not the required 12 places after the number one. The number I tried to input was a thousand times higher. I adapted by using 1 x 10^12.

We’ve all seen graphics with stacks of money on football fields or bills placed end to end, circling the globe, or to the moon and back; none of those measurements resonated with me. I wanted to try measurements that myself and others are more experienced with, like how long is a year, and more personal and down-to-earth such as heartbeats.

How many dollars a day is a trillion since the year One? The year 1AD was a long time ago. We’ll call it 2020 years ago because rounding down a touch barely changes the end result. Multiplying years by 365, we get 737,700. Channelchek readers are sharp and would know this is wrong, so I went back and multiplied by 365.25 to account for leap years (which certainly existed then). So the number of days since the year one, before Jesus learned to walk, is 737,805. That’s a lot of days! The question is, how much money per day would you have to collect each day since the calendar switched from BC to AD to hit a trillion? Simple division tells us $1,355,371.68 per day, each and every day (anno domini).

That result, for my digestion, is easier to comprehend; I have a sense of how long a year is and understand millions better than trillions or even billions. Multiplying by 1.9 I learn, the amount of the current stimulus package, if paid back without interest, over 2020 years would equate to daily installments of $2,575,206.19. Wow!

A second way I looked at one trillion is how many dollars per heartbeat over a lifetime would you have to receive in order to have a trillion dollars and also $1.9 trillion. The CDC lists the average life span as 79 years (rounded up from 78.7). The average healthy heartbeat averages 70 per minute. 70 per minute is 4200 per hour, and in 24 hours, 100,800 over a day. Again allowing for leap years, 100,800 x 365.25 is 36,817,200 beats per year.

If you live for only 79 years, you will have had about 2,908,558,800 heart beats according to this math. A quick search around the medical sites tells me that our non-exact science (fuzzy math) largely agrees with theirs. Dividing one trillion into almost 3 billion heartbeats equals 343.81, or by this example, you’d have to receive $343.81 for every heartbeat from your first breath until your last to reach $1 trillion.

In stimulus package terms (*1.9), The American Rescue Plan is the same dollar amount as an individual’s lifetime of heartbeats at $653.24 per beat.

Take-Away

There’s a line in the movie Austin Powers where, after being frozen since the 1960s, the villain, Dr. Evil is thawed and declares he wants to hold the world ransom for “One Million Dollars.” He’s quickly reminded that $1 million is not that big of a deal anymore. He quickly upped the number. When we hear or see something often, we begin to become numb to what it means, or in the case of large numbers, the true magnitude. Today, billionaires are the new millionaires, and a trillion doesn’t sound like much now that the US is in debt by tens-of-trillions.

Becoming grounded often means understanding what we’re actually looking at. Although the above was fun and surprising for me in some ways, I prefer to look at these large numbers, particularly as it relates to debt in this way. Suppose the full US national debt is $28 trillion while US GDP (the size of the economy) is $22 trillion. That is a debt-to-GDP ratio of 127%, which exceeds World War II levels. The trend in the US, even during the booming Trump years, was not paying down debt but increasing it. This trend is not economically sustainable.

Paul Hoffman

Managing Editor, Channelchek

Suggested Reading

The Correlation Between Stocks and Unemployment

Who Gets to Participate in Private Offerings?

What is the Future of Entertainment Consumption?

Small Cap Names in a Big Crypto Market

InPlay Oil (IPOOF)(IPO:CA) – Estimates Raised to Reflect New Price Deck

Posted on March 10, 2021 by Admin

Wednesday, March 10, 2021

InPlay Oil (IPOOF)(IPO:CA)
Estimates Raised to Reflect New Price Deck

As of April 24, 2020, Noble Capital Markets research on InPlay Oil is published under ticker symbols (IPOOF and IPO:CA). The price target is in USD and based on ticker symbol IPOOF. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target. InPlay Oil is a junior oil and gas exploration and production company with operations in Alberta focused on light oil production. The company operates long-lived, low-decline properties with drilling development and enhanced oil recovery potential as well as undeveloped lands with exploration possibilities. The common shares of InPlay trade on the Toronto Stock Exchange under the symbol IPO and the OTCQZ Exchange under the symbol IPOOF.

Michael Heim, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

We are raising our oil price estimates. We have increased our 2020-4Q WTI oil price estimate to $55 from $45 and our 2021 WTI oil price estimate to $60 from $50. Our long-term oil price forecast remains at $50. IPOOF is expected to release 4Q and 2020 results on March 17.

Higher oil prices means higher revenues and earnings. We are increasing our 2020-4Q revenues and earnings estimate to C$14.5 million (up from C$11.9 million) and C$0.00 per share (up from -C$0.04), respectively. We are also increasing our 2021 revenue and earnings estimates to C$70.5 million (up from C$62.3) and C$0.14 per share (up from -C$0.10) …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Release – 1-800-Flowers.com (FLWS) – Unwraps New Birthday Gifting Hub

Posted on March 10, 2021 by Admin

Party On! 1-800-FLOWERS.COM, Inc. Unwraps New Birthday Gifting Hub

Exclusive Gifts, Party Decor, and Digital Resources Provide Customers with Thoughtful Ideas to Bring Happiness to Everyone’s Special Day

Company to Donate 20% of the Net Proceeds* from Each Gift Purchased from Specially Curated BIRTHYAY! Gifts Collection to Smile Farms®, its Signature Philanthropic Partner

MELVILLE, N.Y.–(BUSINESS WIRE)–CARLE PLACE, N.Y., March 10, 2021 /PRNewswire/ — Today, 1-800-FLOWERS.COM, Inc. (NASDAQ: CMTL) introduced a new hub for birthday gifting, providing customers with thoughtful ways to celebrate the important people in their lives. A birthday gift guide features trending products and unique offerings from across the company’s family of brands, including special floral bouquets, bountiful gift baskets, customized décor, and gourmet treats. In addition, customers can shop from a specially curated birthday gifts collection that helps give back to the differently abled community through job creation and empowerment. Plus, engaging digital content and fun resources provide inspiration for creating memorable moments with friends and loved ones, whether near or far.

“During this time of virtual celebrations, the need for people to express and connect has led to an increased consumer demand for products and services to help commemorate important occasions such as birthdays,” says Alfred Palomares, Vice President, Merchandising, 1-800-Flowers.com. “We are excited to provide our customers with creative solutions from across our family of brands to enhance the celebratory experience, whether through intimate gatherings, online bashes, or drive-by car parades.”

View original release at 1-800-FLOWERS.COM

Source: 1-800-FLOWERS.COM, Inc.

Release – Comtech Telecommunications (CMTL) – Awarded $3.1 Million in Orders for Statewide Next Gen 911

Posted on March 10, 2021 by Admin

Comtech Telecommunications Corp. Awarded $3.1 Million in Orders for Statewide Next Generation 911 Technologies and Services

MELVILLE, N.Y.–(BUSINESS WIRE)–March 10, 2021 — Comtech Telecommunications Corp. (NASDAQ: CMTL) a world leader in secure and highly reliable communication technologies, announced today, that during its second quarter of fiscal 2021, its Safety & Security Technologies group, which is part of Comtech’s Commercial Solutions segment, was awarded $3.1 million of additional funding on a previously announced statewide contract to design, deploy, and operate Next Generation 911 (“NG911”) services for the State of South Carolina. With these incremental orders, the contract which is valued at up to $54.0 million has now been funded $20.0 million to date.

The original contract award, which was won during the fourth quarter of fiscal 2020, is for implementation of Comtech’s NG911 services that will provide citizens with advanced communication capabilities when calling for emergency services, including police, fire and emergency medical services. These incremental orders, through use of Comtech’s Next Generation Core Services (“NGCS”), will enable the State of South Carolina to offer a seamless, coordinated and efficient NG911 system to this initial group of the state’s local 911 centers. In addition, a portion of this new funding represents certain of these centers purchasing state-of-the-art Solacom NG911 call handling solutions.

“These orders reinforce our partnership in providing the highest performance and reliability standards to support South Carolina with mission-critical emergency services and equipment,” said Fred Kornberg, Chairman of the Board and Chief Executive Officer of Comtech Telecommunications Corp.

Comtech’s highly reliable technologies enable the successful handling of over five million 911 calls and texts each month. For more information about Comtech’s 911 products and services, visit www.comtech911.com.

Comtech Telecommunications Corp. is a leader in the global communications market headquartered in Melville, New York. With a passion for customer success, Comtech designs, produces and markets advanced secure wireless solutions to more than 1,000 customers in more than 100 countries. For more information, please visit www.comtechtel.com.

Certain information in this press release contains statements that are forward-looking in nature and involve certain significant risks and uncertainties. Actual results could differ materially from such forward-looking information. The Company’s Securities and Exchange Commission filings identify many such risks and uncertainties. Any forward-looking information in this press release is qualified in its entirety by the risks and uncertainties described in such Securities and Exchange Commission filings.

Media Contact:

Michael D. Porcelain, President and Chief Operating Officer
Comtech Telecommunications Corp.
631-962-7000

info@comtechtel.com

Source: Comtech Telecommunications Corp.

Release – Voyager Digital (VYGVF) – Announces March Interest Mania Rate Increases

Posted on March 10, 2021 by Admin

Voyager Digital Announces March Interest Mania Rate Increases

NEW YORK, March 10, 2021 /CNW/ – Voyager Digital Ltd. (“Voyager” or the “Company”) (CSE: VYGR) (OTCQB: VYGVF) (FRA: UCD2), a publicly-traded, licensed crypto-asset broker that provides investors with a turnkey solution to invest in and trade crypto assets, today announced Voyager’s interest rate hike campaign – March Interest Mania. Voyager customers will now earn increased APRs on the respective assets as follows:*

USDC 9.00%
BTC 6.25%
ETH 5.25%
DOT 8.00%
ADA 5.25%
LINK 5.50%
LTC 6.50%

“At Voyager, we put our community first, as evidenced by our industry leading rates that empower our users to build wealth by investing in digital assets and earning significant interest on the Voyager platform,” said Steve Ehrlich, Co-founder and CEO of Voyager. “Our focus on the retail investor, with our zero-commission platform and extensive interest program, positions Voyager as the platform of choice for investing in and earning interest on digital assets. These new rates are retroactive to the beginning of March, rewarding our loyal users for their continued support.”

Voyager offers interest on a total of 24 digital assets (see the full interest offering here: Interest Program), and through the VGX incentive program, offers interest boosts of 1 percentage point on BTC and USDC, allowing investors to earn up to 10% on USDC, 7.25% on BTC, and 6.25% on Ethereum when holding at least 10,000 VGX tokens. Voyager also recently unveiled its new loyalty program which will take effect once the official Voyager Token swap takes place later in 2021. Interested investors can find out about the new program here: VGX Loyalty Program.

*Additional terms and restrictions apply, including account balance minimums. APRs are subject to change. Actual rate of return will vary based upon account activity. Customer digital assets in the Interest Program are not subject to FDIC or SIPC protections. Please see the Interest Program Terms and Conditions for further details. For more information on Voyager, please visit https://www.investvoyager.com. The Voyager app is available for Android and iPhone.

About Voyager Digital Ltd.

Voyager Digital Ltd. is a crypto-asset broker that provides retail and institutional investors with a turnkey solution to trade crypto assets. Voyager offers customers best execution and safe custody on a wide choice of popular crypto-assets. Voyager was founded by established Wall Street and Silicon Valley entrepreneurs who teamed to bring a better, more transparent and cost-efficient alternative for trading crypto-assets to the marketplace. Please visit us at https://www.investvoyager.com for more information and to review the latest Corporate Presentation.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. No securities regulatory authority has either approved or disapproved of the contents of this press release.

Forward Looking Statements

Certain information in this press release, including, but not limited to, statements regarding future growth and performance of the business, momentum in the businesses, future adoption of digital assets, and the Company’s anticipated results may constitute forward looking information (collectively, forward-looking statements), which can be identified by the use of terms such as “may,” “will,” “should,” “expect,” “anticipate,” “project,” “estimate,” “intend,” “continue” or “believe” (or the negatives) or other similar variations. Because of various risks and uncertainties, including those referenced below, actual events or results may differ materially from those reflected or contemplated in such forward-looking statements. Forward looking statements are subject to the risk that the global economy, industry, or the Company’s businesses and investments do not perform as anticipated, that revenue or expenses estimates may not be met or may be materially less or more than those anticipated, that trading momentum does not continue or the demand for trading solutions declines, customer acquisition does not increase as planned, product and international expansion do not occur as planned and those other risks contained in the Company’s public filings, including in its Management Discussion and Analysis and its Annual Information Form (AIF). Factors that could cause actual results of the Company and its businesses to differ materially from those described in such forward-looking statements include, but are not limited to, a decline in the digital asset market or general economic conditions; the failure or delay in the adoption of digital assets and the blockchain ecosystem by institutions; a delay or failure in developing infrastructure for the trading businesses or achieving mandates and gaining traction; failure to grow assets under management, an adverse development with respect to an issuer or party to the transaction or failure to obtain a required regulatory approval. In connection with the forward-looking statements contained in this press release, the Company has made assumptions that no significant events occur outside of the Company’s normal course of business and that current trends in respect of digital assets continue. Forward-looking statements, past and present performance and trends are not guarantees of future performance, accordingly, you should not put undue reliance on forward-looking statements, past performance or current trends. Information identifying assumptions, risks and uncertainties relating to the Company are contained in its filings with the Canadian securities regulators available at www.sedar.com. The forward-looking statements in this press release are applicable only as of the date of this release or as of the date specified in the relevant forward-looking statement and the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after that date or to reflect the occurrence of unanticipated events. Readers are cautioned that past performance is not indicative of future performance and current trends in the business and demand for digital assets may not continue and readers should not put undue reliance on past performance and current trends. All figures are in U.S. dollars unless otherwise noted.

Investor Relations:
Michael Legg
(212) 547-8807
mlegg@investvoyager.com

Phil Carlson / Scott Eckstein
(212) 896-1233 / (212) 896-1210
pcarlson@kcsa.com / seckstein@kcsa.com

Media:
Anthony Feldman / Raquel Cona
(347) 487-6194 / (212) 896-1204
afeldman@kcsa.com / rcona@kcsa.com

Angus Campbell
44 7881 625098
angus@nominis.co

Source: Voyager Digital Ltd.

Release – Cocrystal Pharma (COCP) – Extends Drug Discovery Collaboration with HitGen and InterX

Posted on March 10, 2021 by Admin

Cocrystal Pharma Extends Drug Discovery Collaboration with HitGen and InterX

BOTHELL, Wash, March 10, 2021 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the SARS-CoV-2 virus, hepatitis C viruses and noroviruses, announces an extension of its drug discovery collaboration with HitGen, a biotech company with an innovative DNA Encoded Library technology, and InterX Inc., a computer software company with a biomolecular simulation for drug discovery. The collaboration was initiated in September 2017 and will now continue through August 2023.

Through this collaboration, Cocrystal, HitGen and InterX scientists are applying HitGen’s DNA-encoded library (DEL) technology platform, Cocrystal’s structure-based drug discovery platform technology, and InterX’s computational science to develop novel antiviral lead candidates. The DEL technology combines the power of molecular biology, combinatorial chemistry, high throughput sequencing and advanced informatics to identify potential drug candidates. Cocrystal applies its technology to determine the cocrystal structures of the potential drug candidates identified from the DEL library. This structural information is then combined with InterX’s advanced computer algorithms to predict inhibitor-target interactions. A Joint Steering Committee comprised of representatives from all three companies is overseeing the collaboration.

“This collaboration represents a truly innovative and important approach to drug discovery in which we combine three novel platforms to generate and select molecules that could lead to superior drugs,” said Gary Wilcox, Ph.D., Chairman and Chief Executive Officer of Cocrystal. “We view this collaboration as a long-term relationship with the potential to build Cocrystal’s platform and expand our pipeline with high-value compounds for future development.”

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected term and the results of Cocrystal’s collaboration with HitGen and InterX. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, HitGen’s DNA Encoded Library technology and InterX software performing as expected, potential disagreements with HitGen or InterX resulting in delays or termination of the collaboration, and the results of future preclinical and clinical studies. The economic and unknown impacts of Covid-19 could result in unanticipated material adverse effects on HitGen, InterX or Cocrystal. Further information on our risk factors is contained in our filings with the SEC, including our Prospectus Supplement dated August 26, 2020 and our Annual Report on Form 10-K for the year ended December 31, 2020, as amended and supplemented by the Quarterly Reports on Form 10-Q for the three months ended June 30, 2020 and the three months ended September 30, 2020. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Investor Contact:

LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com

Source: Cocrystal Pharma, Inc.

Great Lakes Dredge & Dock (GLDD)A Nice Win on Boston Harbor

Chakana Copper Closes Second Tranche of Private Placement Gold Fields Exercises Participation Right

Palladium One Drilling at Kaukua South Extends Mineralization Into “Gap Zone”

Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results

PDS Biotech Announces that its COVID-19 Vaccine Consortium Received a Commitment from The Ministry of Science, Technology and Innovation of Brazil (MCTI) to fund Clinical Development and Commercialization of PDS0203 with an Award of up to ~US$60 Million

PDS Biotechnology Corp (PDSB)Versamune-based COVID-19 Vaccine Consortium Received Brazilian Government Grant

Capstone Turbine Enters Into A New Original Equipment Manufacturer (OEM) Agreement With European-Based Clean Energy Company, B+K – Expanding The Application Of Microturbine Technologies Not Reliant On Fossil Fuels

$1.9 Trillion in Terms we can Better Relate To

InPlay Oil (IPOOF)(IPO:CA)Estimates Raised to Reflect New Price Deck

Party On! 1-800-FLOWERS.COM, Inc. Unwraps New Birthday Gifting Hub

Comtech Telecommunications Corp. Awarded $3.1 Million in Orders for Statewide Next Generation 911 Technologies and Services

Voyager Digital Announces March Interest Mania Rate Increases

Cocrystal Pharma Extends Drug Discovery Collaboration with HitGen and InterX

Great Lakes Dredge & Dock (GLDD)
A Nice Win on Boston Harbor

PDS Biotechnology Corp (PDSB)
Versamune-based COVID-19 Vaccine Consortium Received Brazilian Government Grant

InPlay Oil (IPOOF)(IPO:CA)
Estimates Raised to Reflect New Price Deck